Highlights

  • DAYBUE net product sales reached US$125 million in the June 2026 quarter, the highest quarterly sales since launch.
  • Neuren upgraded 2026 Royalty income guidance to US$53–56 million following Acadia's revised sales outlook.
  • STIX powder formulation adoption reached around 40% of U.S. DAYBUE patients by quarter-end.
  • European expansion progressed with a positive regulatory opinion supporting a planned German launch in Q4 2026.

Neuren Pharmaceuticals (ASX:NEU) has reported its strongest quarter yet from DAYBUE, the Rett syndrome treatment licensed to U.S. partner Acadia Pharmaceuticals, leading to another upgrade in the company's expected 2026 royalty income.

The 5 August 2026 update showed DAYBUE net product sales of US$125 million for the June quarter, representing growth of 30% compared with the prior corresponding period and 24% compared with the March quarter.

Neuren receives royalty income from DAYBUE sales rather than recording product Revenue directly. The royalty stream has become the company's primary Earnings source as the treatment continues its commercial rollout.

What Was Announced?

DAYBUE (trofinetide) is an oral treatment for Rett syndrome, a rare neurodevelopmental disorder that primarily affects girls. Neuren developed the therapy and licensed North American rights to Acadia Pharmaceuticals, which markets DAYBUE and pays Neuren a tiered royalty on net sales.

For Q2 2026, Acadia reported DAYBUE net sales of US$125 million, generating royalty income of US$12.9 million for Neuren.

The royalty income increased 34% year-on-year and 24% quarter-on-quarter.

Following the sales performance, Acadia increased its full-year 2026 DAYBUE sales guidance to US$480–510 million from the previous range of US$460–490 million.

Neuren subsequently increased its own 2026 royalty income guidance to US$53–56 million from US$50–54 million.

A key contributor to patient adoption has been STIX, a powder formulation of DAYBUE designed to improve dosing convenience. Neuren reported that around 40% of U.S. DAYBUE patients were using the STIX formulation by quarter-end.

DAYBUE also received a positive opinion from the European Union's Committee for Medicinal Products for Human Use, with a German launch expected in early Q4 2026.

Why This Matters

For Neuren (ASX:NEU), DAYBUE royalties represent the company's main source of operating income, meaning commercial sales directly influence earnings expectations.

The latest guidance upgrades from both Acadia and Neuren indicate continued commercial expansion following the initial U.S. launch.

The STIX formulation provides an additional product format aimed at improving treatment convenience, while European market entry could provide another source of royalty growth beyond the existing U.S. market.

However, DAYBUE remains concentrated around one product and one licensing partner. Future royalty performance will continue to depend on prescription growth, market access and Acadia's commercial execution.

Company Background

Neuren Pharmaceuticals (ASX:NEU) is a New Zealand-founded biopharmaceutical company focused on treatments for neurodevelopmental disorders.

Its lead commercial asset, trofinetide, is marketed in the United States as DAYBUE through Acadia Pharmaceuticals. Neuren receives royalty income from sales of the product.

The company's development pipeline includes NNZ-2591 (ercanetide), a synthetic analogue being evaluated across several genetic neurodevelopmental conditions including Phelan-McDermid syndrome, Pitt Hopkins syndrome, Angelman syndrome and hypoxic ischemic encephalopathy.

The NNZ-2591 programs have received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration (FDA).

Financial Position

Neuren generated royalty income of US$12.9 million in Q2 2026, with full-year 2026 royalty guidance now upgraded to US$53–56 million.

The company did not disclose a specific cash balance in the announcement reviewed for this article.

Neuren has historically operated using royalty income generated from commercial partnerships, and investors should refer to the company's latest financial disclosures for updated cash information.

What Comes Next?

The next milestones for Neuren (ASX:NEU) include the planned German DAYBUE launch in early Q4 2026 and continued STIX adoption across the U.S. patient base.

Further clinical developments include a Japan trial readout related to a separate trofinetide indication expected between September and November 2026.

The company is also progressing NNZ-2591 Phase 3 programs across Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome.

Acadia has maintained its longer-term target of US$700 million in DAYBUE sales by 2028, providing a reference point for future commercial performance.

Risks

Neuren (ASX:NEU) remains dependent on a single royalty stream linked to DAYBUE and its relationship with Acadia Pharmaceuticals. Changes in prescriptions, pricing, reimbursement or partner strategy could affect royalty income. European commercial rollout may face country-specific reimbursement timelines. The NNZ-2591 pipeline remains in clinical development, and Phase 3 trials may not deliver successful outcomes or lead to regulatory approval. Royalty guidance remains subject to future commercial performance.

Investor Takeaway

Neuren has reported record DAYBUE sales and upgraded its 2026 royalty outlook following continued commercial growth from its key licensed product.

The STIX formulation and European expansion provide additional growth opportunities beyond the existing U.S. market, while the broader NNZ-2591 pipeline offers future development potential.

However, Neuren's near-term earnings remain concentrated around DAYBUE and Acadia's commercial performance. Progress across additional indications and geographic markets will be important for reducing reliance on the current royalty stream.